Want to see NAUT full AI Analyst Report?
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(127.27% Upside)
Action:Reiterated
Date:10/09/26
The score is held back primarily by weak financial performance—minimal revenue, substantial ongoing losses, and significant cash burn—despite low leverage. Offsetting factors include constructive near-term technical momentum (price above key moving averages with positive MACD) and an earnings-call backdrop showing cost control, a multi-year runway, and a clearer proteoform commercialization plan, though broadscale delays and expected fundraising increase risk.
Positive Factors
Proteoform differentiation
The platform’s reported proteoform resolution and reproducibility could provide a meaningful technical advantage in research and drug discovery. If validated across additional assays and customers, this differentiation may support adoption, recurring consumables demand, and a defensible position in a specialized proteomics market.
Negative Factors
Minimal commercial scale
Revenue remains extremely small relative to the company’s operating cost base, showing that commercialization has not yet reached meaningful scale. Continued large operating losses leave profitability dependent on successful future instrument placements, consumable adoption, and service growth rather than an established recurring revenue foundation.
Read all positive and negative factors
Positive Factors
Negative Factors
Proteoform differentiation
The platform’s reported proteoform resolution and reproducibility could provide a meaningful technical advantage in research and drug discovery. If validated across additional assays and customers, this differentiation may support adoption, recurring consumables demand, and a defensible position in a specialized proteomics market.
Read all positive factors
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$286.32M
Dividend YieldN/A
Average Volume (3M)5.36M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth14.45%
CountryUS
Employees127
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding127,255,226
10 Day Avg. Volume14,073,109
30 Day Avg. Volume5,358,853
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue955.41
Enterprise Value/Gross Profit-103.91
Enterprise Value/Ebitda-3.38
Forecast
1Y Price Target
$3.83Price Target Upside335.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$548.33K
Nautilus Biotechnolgy Business Overview & Revenue Model
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, w...
How the Company Makes Money
Nautilus Biotechnology’s commercial revenue model is intended to be based on selling and/or placing its proteomics instruments and then generating recurring revenue from consumables/reagents used with those instruments, plus software and related s...
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Jul 28, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Neutral
The call highlights strong technical and scientific momentum around proteoform capabilities (unique resolution, reproducible assays, collaborations, and a clear proteoform commercialization roadmap) and demonstrates cost discipline. However, meaningful commercial revenues remain nascent, the broadscale application is delayed and requires long-duration work, the commercial organization is small, and the company expects to need additional capital before mid-2027. The positives on technology, customer enthusiasm, and a staged product launch are balanced by execution and financing risks tied to broadscale delays and limited near-term revenue.Positive Updates
Proteoform Technical Breakthroughs and Validation
Demonstrated unique single-molecule proteoform resolution (tau proteoform preprint with collaborators) and reproducible alpha-instrument data at a median CV of ~5.5% versus an industry norm ~25%, enabling new biological insights (APOE–tau link, model system differences).
Negative Updates
Broadscale Application Delay
Broad proteome (broadscale) application is behind the company's prior timeline; assay configuration changes in Q2 did not sufficiently improve probe performance and the program will not support a 2027 general availability at target specifications.
Read all updates
Q2-2026 Updates
Positive
Negative
Proteoform Technical Breakthroughs and Validation
Demonstrated unique single-molecule proteoform resolution (tau proteoform preprint with collaborators) and reproducible alpha-instrument data at a median CV of ~5.5% versus an industry norm ~25%, enabling new biological insights (APOE–tau link, model system differences).
Read all positive updates
Company Guidance
The company reiterated near‑term commercial and financial guidance: Q2 revenue was $0.2M (full‑year revenue guidance ~ $0.5M), total Q2 operating expenses $15.9M (R&D $9.6M; SG&A $6.3M), net loss $14.5M ($0.11/share), cash $129.2M (down $14.2M in Q2) and a cash runway into Q1 2028; full‑year opex is now expected below prior guidance (YOY growth <10%). Strategically, they’re tripling proteoform headcount, halving broadscale staff so application R&D is ~2/3 proteoforms/1/3 broadscale; roadmap targets: beta instrument placement in 2026, pre‑orders early 2027 and shipments mid‑2027, tau and AKT1 consumable GA mid‑2027 (AKT1 early access late‑2026), ~100x sample‑input reduction early‑2027, CSF for tau in 2028, ~20 proteoform assays by mid‑2028, instrument list ~ $1M and per‑sample pricing in the low thousands, and anticipated fundraising between now and mid‑2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.75M | -6.46M | -6.35M | -5.71M | 0.00 | -2.84M |
| EBITDA | -53.74M | -52.54M | -64.43M | -57.97M | -60.08M | -47.47M |
| Net Income | -56.52M | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | ||||||
| Total Assets | 163.58M | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 84.03M | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 27.82M | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 32.46M | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 131.11M | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | ||||||
| Free Cash Flow | -51.86M | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -50.23M | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 27.49M | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 1.45M | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Technical Analysis
Positive
0.88
Price Trends
1.09
Positive
1.58
Positive
2.07
Positive
Market Momentum
0.26
Negative
75.47
Negative
68.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Positive. The current price of 0.88 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.09, and below the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 75.47 is Negative, neither overbought nor oversold. The STOCH value of 68.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 68 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $286.32M | -5.00 | -37.58% | ― | ― | 14.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $121.26M | -1.80 | -27.23% | ― | -13.23% | 12.29% | |
50 Neutral | $154.76M | -1.30 | -136.27% | ― | ― | 27.94% | |
45 Neutral | $51.54M | -1.17 | -71.71% | ― | ― | 73.44% | |
41 Neutral | $10.48M | -0.14 | -152.59% | ― | ― | ― |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
2.17
1.28
143.82%
VTGN
VistaGen Therapeutics
0.23
-3.68
-94.22%
KLRS
Kalaris Therapeutics
2.26
-2.50
-52.52%
SEER
Seer
2.15
-0.06
-2.71%
ABOS
Acumen Pharmaceuticals
2.02
-0.10
-4.72%
Nautilus Biotechnolgy Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Nautilus Biotechnology Establishes New At-The-Market Offering
Neutral
Sep 11, 2026
On September 11, 2026, Nautilus Biotechnology entered into a new sales agreement with TD Securities (USA), LLC, under which TD Cowen will act as sales agent for an at-the-market equity offering of up to $125 million in common stock, with the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.